预约演示
更新于：2025-12-15
Florbetaben F-18
氟[¹⁸F]贝他苯
更新于：2025-12-15
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C21H26FNO3 |
InChIKeyNCWZOASIUQVOFA-FWZJPQCDSA-N |
CAS号902143-01-5 |
关联
46
项与 氟[¹⁸F]贝他苯 相关的临床试验NCT07169630
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer s Disease (AD) or Mild Cognitive Impairment (MCI)
CTIS2023-503705-10-00
Patient- and care-related benefits of amyloid PET imaging (ENABLE)
NCT05617014
Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4)
100 项与 氟[¹⁸F]贝他苯 相关的临床结果
登录后查看更多信息
100 项与 氟[¹⁸F]贝他苯 相关的转化医学
登录后查看更多信息
100 项与 氟[¹⁸F]贝他苯 相关的专利（医药）
登录后查看更多信息
187
项与 氟[¹⁸F]贝他苯 相关的文献（医药）2025-09-01AMERICAN JOURNAL OF NEURORADIOLOGY
Concordance between Centiloid Quantification and Visual Interpretation of Amyloid PET Scans across the Alzheimer Disease Continuum
Article
作者: Razlighi, Qolamreza R ; Glodzik, Lidia ; Nordvig, Anna Starikovsky ; Hojjati, Seyed Hani ; Khalafi, Mohammad ; Wang, Xiuyuan Hugh ; Foldi, Nancy S ; Tanzi, Emily B ; Pahlajani, Silky ; Butler, Tracy A ; Chiang, Gloria C ; Zhou, Liangdong ; de Leon, Mony J ; Li, Yi
BACKGROUND AND PURPOSE:
Accurate identification of cerebral β-amyloid (Aβ) accumulation is crucial for diagnosing Alzheimer disease (AD) and determining eligibility for anti-Aβ therapies. The Centiloid (CL) scale has emerged as a standardized method to harmonize Aβ PET quantification across different tracers and sites. We aimed to evaluate the concordance between CL quantification and visual interpretation in a cohort of cognitively impaired (CI) and unimpaired (CU) participants who underwent Aβ PET.
MATERIALS AND METHODS:
Two hundred twenty-one participants (mean age 69 ± 12.3 years) were prospectively enrolled in AD studies and underwent 247 Aβ PET scans, including 157 with [11C]-Pittsburgh compound B (PiB) and 90 with [18F]-florbetaben (FBB). Standardized uptake value ratios (SUVRs) were converted to the CL scale following Global Alzheimer's Association Interactive Network guidelines. Percent agreement and κ statistics were used to evaluate the concordance between CL thresholds and visual interpretation in determining Aβ positivity.
RESULTS:
The highest concordance rate for the whole cohort was 93% by using a CL cutoff of 18 (κ coefficient 0.84). Using FBB, the concordance rate was highest by using a CL cutoff of 24 (97%), whereas the concordance rate for PiB peaked at 94% at a CL cutoff of 18. Concordance was higher in negative rather than positive Aβ PET cases, 98% versus 90%. Concordance was slightly higher in CI participants compared with CU (96% versus 93%). Disagreement commonly occurred when focal areas of Aβ positivity were identified on visual interpretation but did not meet the threshold globally by CL quantification.
CONCLUSIONS:
Global CL quantification of Aβ PET scans is highly concordant with visual interpretation. Combining both methods may provide a more complete assessment of the extent of Aβ deposition in the brain.
2025-07-01JACC-Cardiovascular Imaging
Established and Emerging Fluorine-18–Labeled Cardiac PET Radiotracers
Review
作者: Malhotra, Saurabh ; Pelletier-Galarneau, Matthieu ; Dilsizian, Vasken ; Packard, René R Sevag ; Dorbala, Sharmila ; Chen, Wengen
Positron emission tomography (PET)/computed tomography is a major imaging strategy for cardiovascular disease characterization. Whereas multiple radioisotopes can be used for PET imaging of cardiac disease processes, fluorine-18 (18F) presents key advantages. These include availability as a unit dose given a favorable half-life of 109.7 minutes and a short positron range leading to a high spatial resolution. In this context, there is growing interest in the development of novel 18F-labeled probes applied to cardiac PET imaging, which in turn provide clinicians with new methods to evaluate disease pathways of interest. Beyond 18F-fluorodeoxyglucose, used in routine clinical practice to scrutinize myocardial viability, cardiac sarcoidosis, as well as prosthetic valve and cardiac device infection, new 18F-labeled radiopharmaceuticals have undergone clinical evaluation. These include 18F-flurpiridaz, which was recently approved by the U.S. Food and Drug Administration for myocardial perfusion imaging and that is also amenable to accurate myocardial blood flow quantitation, 18F-sodium fluoride to detect metabolically active epicardial coronary atherosclerotic lesions, and the 18F-labeled amyloid radiotracers florbetapir, flutemetamol, and florbetaben. This review will further explore emerging 18F-labeled probes applied to cardiac sarcoidosis, myocardial innervation, and ongoing fibrosis/fibroblast activation.
2025-05-04Journal of Sulfur Chemistry
Small molecule heterocycles: design and synthesis of novel fluorescent Benzothiazoles for early detection of Alzheimer’s disease
Article
作者: Sharma, Vijay ; Sundaram, G.S.M.
Diagnostic agents capable of imaging β-amyloid (Aβ) plaques at prodromal stages could provide noninvasive tools to assess plaque burden and assist in determining efficacy of disease-modifying therapeutic interventions in vivo. To accomplish this goal, FDA approved 18F-incorporated tracers, such as Florbetapir, Flutemetamol, and Florbetaben may allow quantitative analysis of therapeutic efficacy of disease-modifying treatments that attenuate Aβ pathophysiology in vivo. Although promising, these tracers show high off-target binding. Importantly, current anti-amyloid therapy also targets diffuse amyloid plaques (included in revised NIAAA criteria for detecting AD) and other forms of amyloid plaques. Therefore, molecules capable of detecting both diffuse and fibrillar plaque pathology can potentially offer better quantitative tools for interrogating efficacy of anti-amyloid therapy. To achieve this goal, herein, we report synthesis and characterization of new small organic molecules: ((Z,E)-4-(2-(6-(2-Fluoroethoxy)benzo[d]thiazol-2-yl)vinyl)-N,N-dimethylaniline) 4, ((Z)-4-(2-(6-(2-(2-(3-Fluoropropoxy)ethoxy)ethoxy)benzo[d]thiazol-2-yl)vinyl)-N,N-dimethylaniline) 5a and ((E)-4-(2-(6-(2-(2-(3-Fluoropropoxy)ethoxy)ethoxy)benzo[d]thiazol-2-yl)vinyl)-N,N-dimethylaniline) 5b. We also report preliminary investigations on binding affinity in vitro. While 4 demonstrated a relatively higher affinity, both 5a and 5b showed moderate affinity for Aβ1-42 aggregates in vitro. Furthermore, all 3 agents showed ability to detect Aβ fibrillar and diffuse plaque pathology in brain sections of APP/PS1 transgenic mice and post-mortem confirmed AD human brain tissue sections.
100 项与 氟[¹⁸F]贝他苯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 阿尔茨海默症 | 美国 | 2014-03-19 | |
| 认知功能障碍 | 欧盟 | 2014-02-20 | |
| 认知功能障碍 | 冰岛 | 2014-02-20 | |
| 认知功能障碍 | 列支敦士登 | 2014-02-20 | |
| 认知功能障碍 | 挪威 | 2014-02-20 | |
| 诊断试剂 | 欧盟 | 2014-02-20 | |
| 诊断试剂 | 冰岛 | 2014-02-20 | |
| 诊断试剂 | 列支敦士登 | 2014-02-20 | |
| 诊断试剂 | 挪威 | 2014-02-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 免疫球蛋白轻链淀粉样变性 | 临床3期 | 美国 | 2023-01-13 | |
| 免疫球蛋白轻链淀粉样变性 | 临床3期 | 德国 | 2023-01-13 | |
| 免疫球蛋白轻链淀粉样变性 | 临床3期 | 西班牙 | 2023-01-13 | |
| 免疫球蛋白轻链淀粉样变性 | 临床3期 | 英国 | 2023-01-13 | |
| 老年性心脏淀粉样变性 | 临床3期 | 美国 | 2023-01-13 | |
| 老年性心脏淀粉样变性 | 临床3期 | 德国 | 2023-01-13 | |
| 老年性心脏淀粉样变性 | 临床3期 | 西班牙 | 2023-01-13 | |
| 老年性心脏淀粉样变性 | 临床3期 | 英国 | 2023-01-13 | |
| 转甲状腺素蛋白淀粉样变性心肌病 | 临床3期 | 美国 | 2023-01-13 | |
| 转甲状腺素蛋白淀粉样变性心肌病 | 临床3期 | 德国 | 2023-01-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 145 | 製構壓選醖糧廠衊窪廠(衊鏇築淵繭鏇鑰鏇鑰築) = 遞鏇積襯獵鬱網鑰淵鑰 簾醖糧積獵獵製鬱範選 (簾糧醖選夢廠淵鏇艱繭, 0.23) 更多 | - | 2025-08-01 | |||
临床2期 | 60 | 11C-PBR28+18F-Florbetaben (Amyloid-positive With Cognitive Impairment (AD)) | 鑰鹽構淵襯獵膚選獵餘(衊夢鹽範選壓獵艱膚餘) = 夢獵齋顧蓋獵憲繭衊廠 廠範觸獵願範鑰廠淵鑰 (襯壓鹹齋觸簾製淵積鹽, 0.18) 更多 | - | 2025-03-05 | ||
11C-PBR28+18F-Florbetaben (Amyloid-positive Without Impairment (Preclinical AD)) | 鑰鹽構淵襯獵膚選獵餘(衊夢鹽範選壓獵艱膚餘) = 鬱繭築製糧廠衊鏇簾獵 廠範觸獵願範鑰廠淵鑰 (襯壓鹹齋觸簾製淵積鹽, 0.16) 更多 | ||||||
N/A | 161 | 觸窪網鏇觸廠糧鬱鏇網 = 構衊鹽製襯鬱夢餘製鑰 遞醖構鬱窪築構鹹繭醖 (遞選築範積觸衊獵積鑰, 選遞願鏇餘齋窪構艱鹽 ~ 製鹹廠獵夢選網淵鏇選) 更多 | - | 2024-05-06 | |||
临床1/2期 | 9 | (Cognitive Impairment) | 構蓋夢製遞築艱襯夢鬱(窪觸製觸淵齋積遞構遞) = 範簾膚鑰網選壓蓋憲製 窪餘顧壓範蓋齋夢窪築 (齋鑰衊醖膚築廠蓋鏇繭, 壓願餘簾憲鹽積衊夢窪 ~ 願憲蓋艱鹽製鑰鹹選願) 更多 | - | 2023-09-13 | ||
(No Cognitive Impairment) | 構蓋夢製遞築艱襯夢鬱(窪觸製觸淵齋積遞構遞) = 廠鑰簾繭夢蓋餘顧壓鹽 窪餘顧壓範蓋齋夢窪築 (齋鑰衊醖膚築廠蓋鏇繭, 鏇遞糧衊襯蓋壓獵築夢 ~ 鏇廠夢獵繭製醖衊淵醖) 更多 | ||||||
临床4期 | 218 | 範築廠鹽選鏇網餘築簾 = 範選觸夢選鹹鏇襯鹽衊 糧餘窪齋蓋餘夢蓋廠衊 (糧築齋廠壓窪糧築糧繭, 廠憲窪齋鏇選膚積鬱鹹 ~ 艱鑰獵製憲網鏇製衊蓋) 更多 | - | 2018-11-02 | |||
临床4期 | 205 | 衊鏇夢壓壓夢壓糧選餘(襯願觸齋膚鑰衊膚構範) = 淵網餘窪範網壓構獵齋 網艱鑰觸艱範構願夢範 (顧鹽蓋鏇鹽鹽醖鹽鏇蓋, 59.9 ~ 73.2) 更多 | - | 2017-07-01 | |||
临床3期 | 82 | (In-person-trained interpreters) | 願憲遞繭餘構獵夢鹹蓋(鑰網壓衊鏇鏇糧範鬱繭) = 積艱選簾範糧糧廠廠鬱 窪艱夢夢範廠選醖醖鑰 (製構齋壓鹹築簾繭獵觸 ) 更多 | - | 2016-06-01 | ||
(Electronic training method) | 願憲遞繭餘構獵夢鹹蓋(鑰網壓衊鏇鏇糧範鬱繭) = 餘夢淵襯衊餘淵醖顧襯 窪艱夢夢範廠選醖醖鑰 (製構齋壓鹹築簾繭獵觸 ) 更多 | ||||||
临床3期 | 阿尔茨海默症 β-amyloid-positive | 216 | Florbetaben PET imaging | 願醖顧網鏇築齋膚構蓋(膚醖顧艱醖網壓廠鹹齋) = 齋選構夢衊願餘醖憲簾 遞憲構鬱醖製糧鏇鹹艱 (網鹽窪衊築憲壓夢獵蓋, 93.8 ~ 100) 更多 | - | 2015-08-01 | |
临床1期 | 45 | (FBB+) | 憲鏇廠廠鹽顧艱繭鏇艱(艱糧製築淵艱鬱襯廠選) = 獵範製網餘鑰夢網襯齋 願構鏇夢選餘製鏇膚鹹 (醖觸簾構膚構鑰艱築蓋 ) 更多 | - | 2015-04-01 | ||
(FBB-) | 顧蓋遞膚鹹衊艱願觸願(選淵窪願蓋鏇鑰觸願憲) = 蓋齋鏇餘觸廠繭積鏇淵 糧鏇餘鏇壓製鹹膚構鏇 (襯積鹹鏇製網壓夢廠蓋 ) | ||||||
N/A | - | (AD patients) | 糧醖獵餘獵繭糧築淵鏇(鬱顧鹹齋繭衊壓廠築窪) = 鑰壓鹹淵醖選顧網鏇餘 齋鹽願憲鏇製鹽襯夢範 (衊選夢鑰顧襯觸積襯窪, 0.77 ~ 0.86) 更多 | - | 2013-07-01 | ||
(Healthy volunteers) | 膚獵夢遞餘膚憲糧顧憲(積淵獵製壓衊築膚襯襯) = 夢齋鬱選膚壓鹽蓋窪醖 糧鑰夢膚觸願夢艱遞膚 (膚鬱鹹構構蓋網願繭鏇, 73.9 ~ 88.2) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用